Drugs / MIC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05365672 | May 2022 → Dec 2026 expected | — | TolerogenixX GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05365672 ↗ |
| Modality | Cell therapy | “donor-derived modified immune cells (MIC)” PMID 36368749 ↗ Nov 2022 |
| Route | Intravenous | “Single intravenous infusion of 1.5x10exp8 MIC per kg of body weight” NCT05365672 ↗ |